These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Improving frontline treatment for chronic myeloid leukemia: emerging evidence for use of nilotinib and dasatinib. Erba HP; Pham DC; Zaiden R; Vu H; Tai S Clin Adv Hematol Oncol; 2011 Oct; 9(10):734-45. PubMed ID: 22252576 [TBL] [Abstract][Full Text] [Related]
26. Optimizing therapy for patients with chronic myelogenous leukemia in chronic phase. Kantarjian HM; Cortes J; La Rosée P; Hochhaus A Cancer; 2010 Mar; 116(6):1419-30. PubMed ID: 20120030 [TBL] [Abstract][Full Text] [Related]
27. Targeted drugs in chronic myeloid leukemia. Gora-Tybor J; Robak T Curr Med Chem; 2008; 15(29):3036-51. PubMed ID: 19075651 [TBL] [Abstract][Full Text] [Related]
28. [Research advance on molecular genetics of CML blast crisis]. Zhu HQ; Zhang S; Liu XL Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Feb; 16(1):217-21. PubMed ID: 18315935 [TBL] [Abstract][Full Text] [Related]
29. Treatment patterns and prognostic indicators of response to therapy among patients with chronic myeloid leukemia in Australia, Canada, and South Korea. Whiteley J; Iyer S; Candrilli SD; Kaye JA Curr Med Res Opin; 2015 Feb; 31(2):299-314. PubMed ID: 25427232 [TBL] [Abstract][Full Text] [Related]
30. BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices. Kantarjian H; Cortes J J Natl Compr Canc Netw; 2008 Mar; 6 Suppl 2():S37-42; quiz S43-S44. PubMed ID: 18397680 [TBL] [Abstract][Full Text] [Related]
31. Dasatinib treatment for imatinib resistant or intolerant patients with chronic myeloid leukaemia. Li J; Xu G; Yu S; He L; Guo L J Int Med Res; 2011; 39(2):337-47. PubMed ID: 21672337 [TBL] [Abstract][Full Text] [Related]
32. Dasatinib and nilotinib for imatinib-resistant or -intolerant chronic myeloid leukaemia: a systematic review and economic evaluation. Rogers G; Hoyle M; Thompson Coon J; Moxham T; Liu Z; Pitt M; Stein K Health Technol Assess; 2012; 16(22):1-410. PubMed ID: 22551803 [TBL] [Abstract][Full Text] [Related]
33. Long-term molecular and cytogenetic response and survival outcomes with imatinib 400 mg, imatinib 800 mg, dasatinib, and nilotinib in patients with chronic-phase chronic myeloid leukaemia: retrospective analysis of patient data from five clinical trials. Jain P; Kantarjian H; Alattar ML; Jabbour E; Sasaki K; Nogueras Gonzalez G; Dellasala S; Pierce S; Verstovsek S; Wierda W; Borthakur G; Ravandi F; O'Brien S; Cortes J Lancet Haematol; 2015 Mar; 2(3):e118-28. PubMed ID: 26687797 [TBL] [Abstract][Full Text] [Related]
34. Failure to achieve a complete hematologic response at the time of a major cytogenetic response with second-generation tyrosine kinase inhibitors is associated with a poor prognosis among patients with chronic myeloid leukemia in accelerated or blast phase. Fava C; Kantarjian HM; Jabbour E; O'Brien S; Jain N; Rios MB; Garcia-Manero G; Ravandi F; Verstovsek S; Borthakur G; Shan J; Cortes J Blood; 2009 May; 113(21):5058-63. PubMed ID: 19282457 [TBL] [Abstract][Full Text] [Related]
35. Efficacy of molecular response at 1 or 3 months after the initiation of dasatinib treatment can predict an improved response to dasatinib in imatinib-resistant or imatinib-intolerant Japanese patients with chronic myelogenous leukemia during the chronic phase. Inokuchi K; Kumagai T; Matsuki E; Ohashi K; Shinagawa A; Hatta Y; Takeuchi J; Yoshida C; Wakita H; Kozai Y; Shirasugi Y; Fujisawa S; Iwase O; Yano S; Okamoto S; Oba K; Sakamoto J; Sakamaki H J Clin Exp Hematop; 2014; 54(3):197-204. PubMed ID: 25501110 [TBL] [Abstract][Full Text] [Related]
36. Lack of non-hematological cross intolerance of dasatinib to imatinib in imatinib-intolerant patients with Philadelphia chromosome positive chronic myeloid leukemia or acute lymphatic leukemia: a retrospective safety analysis. Kobayashi Y; Sakamaki H; Fujisawa S; Ando K; Yamamoto K; Okada M; Ishizawa K; Nagai T; Miyawaki S; Motoji T; Usui N; Iida S; Taniwaki M; Uoshima N; Seriu T; Ohno R Int J Hematol; 2011 Jun; 93(6):745-749. PubMed ID: 21594763 [TBL] [Abstract][Full Text] [Related]
37. Imatinib mesylate (STI571) therapy for Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase. Kantarjian HM; Cortes J; O'Brien S; Giles FJ; Albitar M; Rios MB; Shan J; Faderl S; Garcia-Manero G; Thomas DA; Resta D; Talpaz M Blood; 2002 May; 99(10):3547-53. PubMed ID: 11986206 [TBL] [Abstract][Full Text] [Related]
38. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. Syed YY; McCormack PL; Plosker GL BioDrugs; 2014 Feb; 28(1):107-20. PubMed ID: 24420842 [TBL] [Abstract][Full Text] [Related]
39. Dynamics of chronic myeloid leukemia response to dasatinib, nilotinib, and high-dose imatinib. Olshen A; Tang M; Cortes J; Gonen M; Hughes T; Branford S; Quintás-Cardama A; Michor F Haematologica; 2014 Nov; 99(11):1701-9. PubMed ID: 25216683 [TBL] [Abstract][Full Text] [Related]